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ABSTRACT 
The advances in the treatment of testicular cancer are among the great achievements in 
modern medicine and these were only possible through the collaborative efforts among 
cancer researchers around the world. Investigators have been able to address many 
questions regarding the treatment of patients with disease limited to the testis, 
metastasis to the retroperitoneum only, and advanced metastatic disease. Questions 
answered include the chemotherapeutic agents to be used, what combination, the 
intensity of treatment with appropriate dosing, optimal number of cycles of 
chemotherapy according to validated risk stratification, appropriate surgical approaches 
preserving sexual function, treatment of relapsed disease, supportive care measures, 
and survivorship issues for testicular cancer survivors. Today, cure is achievable in 95% 
of patients with testicular cancer and in 80% of patients with metastatic disease. Despite 
remarkable results with frontline and salvage combination chemotherapy, about 10% of 
patients with metastatic testicular cancer remain incurable and novel treatment 
approaches are warranted. This review highlights past and recent discoveries in the 
treatment of patients with testicular cancer.   
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INTRODUCTION 
Testicular cancer is the most common cancer diagnosis in men between 15 and 35 
years of age and the incidence has risen during the past several decades.1 An 
estimated 8,720 cases of testicular cancer will be diagnosed annually in the United 
States.2 The vast majority (95%) of testicular cancer cases are germ cell tumors with 
other testicular neoplasms occurring rarely (sex cord stromal tumors, lymphoma). Germ 
cell tumors may also arise in extragonadal locations including the retroperitoneum and 
the mediastinum.  
Substantial advances have been made in the treatment of testicular cancer and these 
have been among the great achievements in modern medicine. The introduction and 
refinement of cisplatin-based combination chemotherapy revolutionized the treatment of 
testicular cancer. Patients diagnosed with testicular cancer who once had dismal 
prognosis are now curable even in the presence of metastatic disease.3-6 This disease 
has become a model for a curable neoplasm and this review will highlight past and 
present discoveries while emphasizing areas for further investigation.  
PATHOGENESIS AND EPIDEMIOLOGY 
Germ cell tumors are malignancies of primordial germ cells, these are the cells destined 
to be become spermatozoa. As neoplastic transformation occurs, these cells develop 
into various histologies reflecting the broad differentiation capabilities of these cells. The 
first tumorigenic event leading to the development of germ cell tumors occurs in utero 
and this leads to the precursor lesion: intratubular germ cell neoplasia.7,8 In adults, both 
seminoma and non-seminomatous germ cell tumors are preceded by this premalignant 
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entity. Intratubular germ cell neoplasia is present in testicular tissue adjacent to germ 
cell tumors in approximately 90% of adult cases.9 These premalignant lesions carry a 
50% risk of developing testicular cancer within 5 years.10 Intratubular germ cell 
neoplasia are derived from gonocytes which have failed to differentiate into 
spermatogonia and they remain quiescent from the initial insult in utero until hormonal 
changes occur during puberty.    
Testicular germ cell tumors are broadly separated into 2 groups: seminomas and non-
seminomas, each constituting about 50% of the cases. These tumors differ in their 
pathogenesis, histology, clinical course, and response to therapy. Seminomas consist of 
transformed germ cells that resemble the gonocyte but have a differentiation block. 
Non-seminomas consist of several histological subtypes including embryonal 
carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Embryonal carcinoma cell 
lines resemble undifferentiated stem cells, and their patterns of gene expression are 
similar to those of intratubular germ cell neoplasia.11,12 Choriocarcinoma and yolk sac 
tumors have extraembryonic differentiation, and teratoma have somatic differentiation.  
Several candidate genetic loci have been identified as contributors to the pathogenesis 
of testicular cancer.13-15 Germ cell tumors are characterized by the acquisition of extra 
copies of chromosome 12p. This occurs most commonly through an isochromosome 
(i12p).16,17 Chromosome 12q21 contains genes encoding for proteins involved in 
KITLG–KIT signaling.18 It has been postulated that the development of intratubular 
germ-cell neoplasia may involve aberrantly activated KITLG–KIT in utero, which induces 
arrest of embryonic germ cells at the gonocyte stage; subsequently, overexpression of 
embryonic transcription factors such as NANOG, sex-determining-region Y–box 17 
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(SOX17), and octamer-binding transcription factor 3–4 (OCT3/4, also known as POU 
domain, class 5, transcription factor 1 [POU5F1]) leads to suppression of apoptosis, 
increased proliferation, and accumulation of mutations in gonocytes.19  
Single gene mutations are uncommon in testicular cancer. KIT, TP53, KRAS/NRAS, 
and BRAF are genes most commonly mutated in germ cell tumors and are implicated in 
their pathogenesis. Different histologic subtypes possess different gene expression 
profiles that reflect different directions of differentiation.  
The distinct gene expression profiles of germ cell tumors is postulated to be achieved 
through differential epigenetic regulation, in particular DNA methylation.20 Gonocytes 
have almost completely demethylated DNA, and this facilitates the accumulation of 
mutations during cell replication and is implicated in the development of intratubular 
germ cell neoplasia and germ cell tumors thereafter.  
World-wide, there are approximately 72,000 cases and 9,000 deaths per year 
attributable to testicular cancer.21 Epidemiologic studies suggest that the incidence of 
testicular cancer has been rising since the early 1900s.22-26 Genetic and environmental 
factors both in utero and during childhood have been proposed to be responsible for this 
increased incidence. This increase in incidence has been observed only in white males. 
Testicular cancer is less common in African Americans with the incidence among 
African Americans estimated to be one-fourth that of whites.27   
The risk for testicular cancer is increased 8 to 10 fold in the brothers of a person with 
testicular cancer and 4 to 6 fold in the son of a person with testicular cancer when 
compared to an unaffected family member.28 Cryptorchidism occurs in up to 5% of boys 
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born at term and this is the most well characterized risk factor for testicular cancer.29 
The timing of orchiopexy influences the risk of developing testicular cancer. In a cohort 
study conducted in Sweden between 1964 and 1999, 16,983 men who were surgically 
treated for undescended testis were followed for a total of 209,984 person-years. The 
relative risk of testicular cancer among those who underwent orchiopexy before 
reaching age 13 was 2.23 compared with 5.4 in those who underwent orchiopexy at age 
13 or older. This suggests that hormonal changes around puberty have a role in the 
development of testicular cancer. Most patients diagnosed with testicular cancer, 
however, do not have a history of cryptorchidism. A personal history of testicular cancer 
in the contralateral testis confers an approximately 2% risk for a second primary 
testicular neoplasm.30  
CLINICAL PRESENTATION AND DIAGNOSIS 
Most patients are diagnosed with testicular cancer when it is still limited to the testes 
(stage I). The typical presentation is a painless nodule or swelling noted by the patient 
or his partner. Patients less commonly present with pain in the scrotal area or with 
gynecomastia. A minority of patients are diagnosed with symptoms related to metastatic 
disease to the retroperitoneum (stage II) such as back pain or beyond the 
retroperitoneal lymph nodes (stage III) such as cough, hemoptysis, chest pain, and 
headaches. Some patients also present with painless supraclavicular lymph nodes.  
Scrotal ultrasonography revealing a hypoechoic mass is diagnostic of testicular cancer. 
A trans-scrotal testicular biopsy should not be attempted given concern for 
contamination of the scrotum and alteration of the lymphatic drainage of the tumor. 
Staging for testicular cancer is critical; this should be determined with the use of 
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computed tomography (CT) of the chest, abdomen, and pelvis and measurement of the 
levels of tumor markers for germ cell tumors including alpha fetoprotein (AFP) and beta 
human chorionic gonadotropin (β-hCG). Lactate dehydrogenase (LDH) should only be 
checked at the first day of initiating chemotherapy as this can be an indicator of the bulk 
of disease but it is not independently used as a tumor marker or prognostic criterion.   
When a patient presents with a suspicious testicular mass that is confirmed on 
ultrasonography, a radical inguinal orchiectomy is both diagnostic and therapeutic. 
Pathological interpretation of the tumor sample should include the size, histologic 
composition (including percentage of each histologic subtype present in the tumor 
sample), presence or absence of lympho-vascular invasion and rete testis invasion.  
STAGE I TESTICULAR CANCER 
Seminoma 
Patient who present with clinical stage I seminoma are usually cured with orchiectomy 
alone. Adjuvant radiotherapy was an option for many years but this changed after the 
introduction of effective chemotherapy. After orchiectomy, options for patients with 
clinical stage I seminoma include active surveillance, radiation therapy to the para-aortic 
lymph nodes, or a single dose of carboplatin dosed at an area under the concentration x 
time curve [AUC] of 7. Most patients today elect for active surveillance given the low 
chance of disease recurrence. If radiotherapy is the choice, 20 Gy is delivered to the 
ipsilateral retroperitoneal lymph nodes. If the patient has a history of prior surgery in the 
inguinal, pelvic, or scrotal areas, then the radiation field is expanded to include the 
inguinal lymph nodes. The risk for relapse is higher with active surveillance (20%) 
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versus chemotherapy or radiation therapy (4%) but the long-term survival is 
approximately 99% irrespective of the initial options chosen by the patient.31-33 Risk 
factors for relapse in clinical stage I seminoma include involvement of rete testis or 
having a primary tumor larger than 4cm.34 In a Danish population-based study of 1,954 
patients there were 369 relapses (19%). Disease specific survival at the median follow-
up of 15 years was 99%.33 At our institution, the surveillance regimen consists of history 
and physical examination, tumor markers including AFP and hCG, and CT abdomen 
every 4 months during the first year, every 6 months during the second year, and then 
annually during the 3rd, 4th, and 5th year of follow-up. If a patient has history of pelvic, 
inguinal, or other surgery that would alter the lymphatic drainage, then a CT abdomen 
and pelvis is obtained for surveillance.  
Non-seminoma 
For patients with stage I non-seminomatous germ cell tumor, options after orchiectomy 
include active surveillance, nerve-sparing retroperitoneal lymph node dissection, and 
adjuvant chemotherapy with bleomycin-etoposide-cisplatin (BEP) for 1 cycle. Several 
studies have indicated that the long-term cure rates with any of these options is 99%.35-
39 Risk factors for relapse in patients with clinical stage I non-seminoma include the 
presence of lympho-vascular invasion and having embryonal carcinoma as the 
predominant histology in the primary tumor.35,40 The risk for relapse in patients with no 
risk factors is approximately 15% with surveillance; with the presence of risk factors this 
rate increases to approximately 50% with surveillance. In a large retrospective study of 
1,139 patients with clinical stage I non-seminoma, cure rate was 99% in all patients 
irrespective of their initial risk factors for relapse or choice of treatment after 
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orchiectomy.35 Moreover, the vast majority of relapses occurred within 2 years of 
orchiectomy. The preference at our institution is for active surveillance in nearly all 
patients who are able to adhere to the close follow-up schedule. We recommend a 
surveillance program with history and physical examination and tumor markers (AFP 
and hCG) every 2 months during the first year, every 6 months during the second year, 
and annually during years 3, 4, and 5. Imaging should include chest radiography and 
CT abdomen every 4 months during the first year, every 6 months during the second 
year, and annually during years 3, 4, and 5 of follow-up. If a patient has history of pelvic, 
inguinal, or other surgery that would alter the lymphatic drainage, then a CT abdomen 
and pelvis is obtained for surveillance. There are complicated arguments for and 
against any of the 3 options for the management of clinical stage I testicular cancer. 
These are illustrated in Table 1.  
STAGE II TESTICULAR CANCER 
Seminoma 
Patients with stage II seminoma have metastatic disease confined to the retroperitoneal 
lymph nodes. Low volume stage II disease, defined by lymph nodes ≤3cm in diameter, 
can be treated with 30-36 Gy of radiation to the para-aortic and ipsilateral iliac lymph 
nodes.39 In all other patients, the preferred therapy is 3 courses of combination 
chemotherapy with bleomycin-etoposide-cisplatin (BEP) or 4 courses of etoposide-
cisplatin (EP).41 With cisplatin-based combination chemotherapy, cures are achieved in 
98% of patients. Patients who have bulky stage II disease should not undergo 
radiotherapy as the relapse rate is high with radiotherapy.42 Post-treatment residual 
masses can be challenging to interpret in patients with seminoma. These findings 
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usually represent desmoplastic changes; surgical resection of these residual masses 
only rarely shows residual seminoma and can be quite challenging. We typically 
observe patients with post-treatment residual masses < 3cm in diameter. Masses larger 
than 3cm have a higher likelihood of containing residual viable seminoma. In these 
cases, a positron-emission tomographic (PET) scan performed 6 weeks after 
completion of therapy can assist in making the decision whether surgical intervention is 
needed to resect residual retroperitoneal masses.43  
A phase II clinical trial is currently evaluating retroperitoneal lymph node dissection as 
the primary treatment in patients with stage II seminoma and non-bulky disease 
(ClinicalTrials.gov number, NCT02537548). 
Non-seminoma 
Patients with low volume stage II non-seminomatous germ cell tumor have metastatic 
disease confined to the retroperitoneal lymph nodes, lymph node size < 3cm, and 
normal tumor markers (AFP and hCG) post-orchiectomy. These patients are typically 
treated with retroperitoneal lymph node dissection.44 At our institution, patients with high 
volume stage II disease or increasing levels of tumor markers (AFP or hCG) are treated 
with chemotherapy consisting of 3 cycles of BEP or 4 cycles of EP. About 95-99% of 
patients with stage II non-seminoma achieve cures with the above regimens.  
Post-chemotherapy, patients who have persistently enlarged retroperitoneal lymph 
nodes with normal tumor markers (AFP and hCG) should undergo post-chemotherapy 
retroperitoneal lymph node dissection for resection of residual tumor and/or teratoma. 
The management of patients with stage II non-seminoma who have complete serologic 
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and radiographic remission remains unsettled. At our institution, we do not recommend 
retroperitoneal lymph node dissection if the retroperitoneal lymph nodes have 
normalized on CT imaging. In a retrospective study, 141 patients with non-seminoma 
who achieved complete radiographic and serologic remission after first-line 
chemotherapy were followed for a median of 15.5 years with no post-chemotherapy 
retroperitoneal lymph node dissection. The 15-year recurrence-free survival was 90% 
and cancer-specific survival was 97%.45 Given concern for the presence of viable germ 
cell tumor and/or teratoma in some patients with normal-sized post-chemotherapy 
lymph nodes, some investigators recommend post-chemotherapy retroperitoneal lymph 
node dissection in most patients.46 In a meta-analysis, 1,043 patients with metastatic 
non-seminoma treated with cisplatin-based chemotherapy were evaluated and among 
these 588 underwent post-chemotherapy retroperitoneal lymph node dissection while 
455 were followed with surveillance only.47 In patients who underwent post-
chemotherapy resection, the pooled estimates of necrosis, teratoma and active cancer 
were 71%, 24%, and 4% respectively. Among patients who were followed with post-
chemotherapy surveillance only, the pooled estimate of relapse was 5% with a 
retroperitoneal-only relapse rate of 3%. Therefore, post-chemotherapy retroperitoneal 
lymph node dissection can be avoided in approximately 95% of patients with 
radiographic and serologic remission and at our institution these patients are followed 
with surveillance.  
STAGE III TESTICULAR CANCER 
The discovery of cisplatin48 and the refinement of combination chemotherapy 
revolutionized the treatment of metastatic testicular cancer. In 1974, the addition of 
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cisplatin to a regimen of vinblastine and bleomycin achieved 5-year survival rate of 64% 
which was unprecedented compared with previous chemotherapy regimen.4 Cisplatin-
based combination chemotherapy regimens were then refined in multiple subsequent 
studies.3,5,6 Based on a randomized clinical trial showing improved efficacy and less 
toxicity, first-line chemotherapy with 4 cycles of bleomycin-etoposide-cisplatin (BEP) 
became the standard of care for patients with advanced testicular cancer.6 Investigators 
recognized that each additional cycle of chemotherapy caused cumulative toxicity, 
hence randomized trials in patients with low-risk disease showed that 3 cycles of BEP 
had similar outcomes and were non-inferior to BEP x 4 or BEP x 3 plus etoposide-
cisplatin (EP) x 1.5,49 A randomized clinical trial comparing 3 cycles of BEP and 4 cycles 
of EP in patients with low-risk disease favored BEPx3 (4-year event-free survival rate of 
91% vs. 86%) although the difference was not statistically significant (P=0.14).50 For 
patients with low-risk metastatic disease, our preferred regimen is 3 cycles of BEP but 4 
cycles of EP is also considered a standard regimen. Randomized trials have shown 
numerical superiority of BEPx3 over EPx4 although this was not statistically significant.   
After a multinational analysis in 1997, the International Germ-Cell Cancer Collaborative 
Group (IGCCCG) published a consensus statement classifying patients with metastatic 
GCT into good, intermediate, and poor risk disease based on specified prognostic 
criteria: primary tumor site, metastatic sites, and the amplitude of serum tumor marker 
levels.51 This classification was based on an international collaboration evaluating 5,202 
patients with metastatic germ cell tumors. For seminoma: good risk patients were 
defined as having any primary tumor site, no non-pulmonary visceral metastasis (liver, 
brain, bone, or other), and any tumor marker levels (hCG, LDH; AFP by definition is 
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normal in patients with seminoma); intermediate risk patients were defined as having 
non-pulmonary visceral metastasis. For non-seminoma: good risk patients were defined 
as having primary testis or retroperitoneal tumor site and no non-pulmonary visceral 
metastasis and good tumor marker levels (AFP < 1,000 ng/mL, hCG < 5,000 mIu/mL, 
LDH < 1.5 x upper limit of normal); intermediate risk patients were defined as having 
intermediate tumor marker levels (AFP 1,000-10,000 ng/mL, hCG 5,000-50,000 
mIu/mL, LDH 1.5-10 x upper limit of normal); poor risk patients were defined as having 
primary mediastinal tumor site, non-pulmonary visceral metastasis, or poor tumor 
marker levels (AFP > 10,000 ng/mL, hCG > 50,000 mIu/mL, LDH > 10 x upper limit of 
normal).51 Good risk germ cell tumors represented 60% of all metastatic cases with a 5-
year progression-free survival (PFS) of 88% and a 5-year overall survival (OS) of 91%. 
Intermediate risk germ cell tumors represented 26% of all cases with a 5-year PFS of 
75% and a 5-year OS of 79%. The poor risk category represented 14% of patients with 
a 5-year PFS of 41% and a 5-year OS of 48%. 
Using the above risk stratification, the treatment of metastatic testicular cancer has 
been refined according to the patient’s chance for response to first-line chemotherapy 
and risk for relapse. Patients with good risk disease are treated with 3 cycles of BEP 
and 4 cycles of EP and are expected to have > 90% cure rate with first-line 
chemotherapy.3,5,6,49,50 Patients with intermediate risk disease are treated with 4 cycles 
of BEP or 4 cycles of etoposide, ifosfamide, cisplatin (VIP) and are expected to achieve 
> 80% cure rate with first-line chemotherapy.52-54 Patients with poor risk disease are 
treated with 4 cycles of BEP or VIP and are expected to achieve a cure rate of 50-60% 
with first-line chemotherapy.53,55-59 
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The intermediate risk group constitutes a heterogeneous category with varying 
outcomes. At our institution, we consider that 4 cycles of BEP or VIP might be an 
overtreatment in some patients with intermediate risk disease and we recommend 
treatment with 3 cycles of BEP followed by 1 cycle of EP in these select patients. A 
retrospective analysis did not show any difference in survival outcomes among 
intermediate risk patients who received treatment with either of these regimens.60  
Several attempts have been made to intensify first-line therapy with hopes of increasing 
cure rates among patients with intermediate or poor risk disease. Unfortunately, these 
attempts have failed at showing any survival advantage over 4 cycles of BEP or VIP 
and these intensified regimens had more toxicity in clinical trials.52,55-57 Some 
investigators proposed intensification of therapy according to the rate of decline of 
tumor markers (AFP and hCG) in patients with high risk disease after the first or second 
cycle of BEP chemotherapy.58 This strategy resulted in fewer relapses and appeared to 
improve overall survival, albeit at the expense of more toxicity, compared to the control 
arm on this study but not compared to contemporary survival outcomes.59,61  
A novel regimen of paclitaxel-ifosfamide-cisplatin (TIP) has been studied in phase II trial 
enrolling patients with intermediate and poor risk germ cell tumors. Results showed a 
complete response rate of 68% and a partial response rate of 13%.62 With this regimen 
the estimated 3-year PFS and OS for intermediate risk patients was 90% and 100%, 
and for poor risk patients was 63% and 87% respectively. A randomized phase II trial 
comparing BEP vs. TIP as first-line therapy for patients with intermediate and poor risk 
germ cell tumors is ongoing (ClinicalTrials.gov number, NCT01873326).  
RELAPSED TESTICULAR CANCER 
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The most effective salvage regimen for patients with relapsed testicular cancer remains 
unsettled. Patients who relapse after initial chemotherapy, with anatomically confined 
disease, can still be cured by salvage surgery.63 The vast majority of patients, however, 
will be treated with salvage chemotherapy including standard-dose chemotherapy or 
high-dose chemotherapy. Second-line standard-dose chemotherapy options include 
etoposide-ifosfamide-cisplatin (VIP), vinblastine-ifosfamide-cisplatin (VeIP), or 
paclitaxel-ifosfamide-cisplatin (TIP).64-66 
High-dose chemotherapy followed by bone marrow transplant was first investigated at 
Indiana University in 1986.67 Bone marrow transplantation was replaced by peripheral-
blood stem cells in 1996. This allowed for more rapid engraftment and hence fewer 
delays in delivering a second course of high-dose chemotherapy. Among the first 184 
patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplant 
for germ cell tumors that progressed after first-line or second-line cisplatin-based 
chemotherapy, cures were achieved in 70% of patients in the second-line setting and in 
45% of patients who were treated in the third-line or subsequent setting.68 
In an updated analysis from Indiana University, 364 consecutive patients with relapsed 
germ cell tumors were treated with high-dose chemotherapy and autologous peripheral-
blood stem-cell transplant between 2004 and 2014.69 With a median follow-up of 3.3 
years, the 2-year progression-free survival was 60% and the 2-year overall survival 
was 66%. Three hundred three patients received high-dose chemotherapy as second-
line therapy with a 2-year progression-free survival of 63% and 61 patients received 
high-dose chemotherapy as third-line or later therapy with a 2-year progression-free 
survival of 49%. There were 122 patients with platinum refractory disease, defined as 
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tumor progression within 4 weeks of platinum-based chemotherapy, with a 2-year 
progression-free survival of 33%. There were 90 patients with seminoma on this study 
with a 2-year progression-free survival of 90%. Treatment-related death rate was 2.5%.  
Investigators at Memorial Sloan Kettering Cancer Center (MSKCC) pioneered another 
widely used high-dose chemotherapy regimen, which incorporates paclitaxel and 
ifosfamide as induction chemotherapy and stem-cell mobilization followed by high-dose 
carboplatin and etoposide with peripheral-blood stem-cell transplant for three cycles (TI-
CE regimen).70 In a phase I/II trial that enrolled 107 patients, the reported 5-year 
disease-free survival was 47%and overall survival was 52%. Patients who had a 
satisfactory decline in the tumor marker levels during high-dose chemotherapy had 
superior progression-free and overall survival; however, even patients with 
unsatisfactory decline in tumor marker levels could be cured.71  
The choice of initial salvage chemotherapy for relapsed testicular cancer remains 
controversial. One of the challenges is determining which patients should be treated 
with salvage standard-dose chemotherapy versus high-dose chemotherapy. A 
randomized phase III study comparing sequential with a single course of high-dose 
chemotherapy showed superior overall survival in the arm receiving sequential high-
dose chemotherapy.72 A prospective phase III trial did not show a difference in survival 
when comparing etoposide-ifosfamide-cisplatin (VIP) for four cycles versus VIP for three 
cycles followed by high-dose chemotherapy with carboplatin and etoposide plus 
cyclophosphamide for one cycle.73 In 2011, Lorch et al reported outcomes from a large 
multi-institutional database evaluating 1,594 patients with relapsed germ cell tumors.74 
This retrospective study included a diverse patient population stratified to prognostic 
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subgroups according to the International Prognostic Factors Study Group. Patients were 
treated with heterogeneous salvage chemotherapy regimens between 1990 and 2008. 
In this study, high-dose chemotherapy achieved superior outcomes compared with 
standard-dose chemotherapy and there was an overall 56% decrease in the risk of 
progression after first salvage treatment, favoring high-dose chemotherapy. This 
translated into statistically significant improvement in overall survival with high-dose 
chemotherapy in all prognostic subgroups except the low-risk group. The superior 
outcomes with high-dose chemotherapy were more pronounced in patients with 
intermediate, high, or very high risk disease.  
Studies have indicated that patients with high-risk relapsed disease (example: platinum 
refractory, primary mediastinal non-seminoma, and patients with progressive brain 
metastases) can be cured with high-dose chemotherapy.69,70 These results are rarely 
seen with standard-dose chemotherapy in these high risk patients. With high-dose 
chemotherapy, cure rates for patients with relapsed primary mediastinal non-seminoma 
are approximately 25%, for patients with progressive brain metastases approximately 
40%, and for patients with platinum refractory disease approximately 33%.69  
Some investigators advocate the use of high-dose chemotherapy in most patients as 
the second-line regimen, whereas others have proposed the use of high-dose 
chemotherapy only in high-risk patients, those who have had a relapse after receiving 
ifosfamide-based chemotherapy, or those who have had a relapse after two lines of 
standard salvage therapy. Optimal patient selection for high-dose chemotherapy versus 
standard-dose chemotherapy as initial salvage is currently being studied in a 
randomized phase III trial as part of an international collaboration (ClinicalTrials.gov 
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identifier, NCT02375204). This trial (TIGER, or a Randomized Phase III Trial of Initial 
Salvage Chemotherapy for Patients with Germ-Cell Tumors) randomizes patients to 
receive paclitaxel-ifosfamide-cisplatin (TIP) for 4 cycles or ifosfamide plus paclitaxel 
followed by high-dose carboplatin and etoposide for 3 cycles.  
NOVEL APPROACHES IN TESTICULAR CANCER 
Although most patients with metastatic testicular cancer will be cured, about 10% of 
patients have platinum refractory disease and remain incurable. Further advances 
evaluating the biology of this disease and investigating the mechanism of resistance to 
treatment is desperately needed. In the era of targeted therapy and immunotherapy, 
cytotoxic chemotherapy remains the mainstay of treatment for metastatic disease. 
Unfortunately, early studies with molecularly targeted therapies such as imatinib, 
sunitinib, thalidomide, and trastuzumab have yielded negative results.75-78 Studies 
evaluating the activity of immune checkpoint inhibitors are underway and results will be 
reported in the near future.79 Some investigators are evaluating hypomethylating agents 
as means to overcome the mechanism of resistance to platinum chemotherapy in 
patients with relapsed refractory germ cell tumors with early phase clinical trials ongoing 
(ClinicalTrials.gov number, NCT02429466). Other investigators have evaluated the 
genomic profile of platinum refractory germ cell tumors.80,81 Unfortunately, consistent 
targetable genomic alterations have not been identified to date. 
SURVIVORSHIP ISSUES IN TESTICULAR CANCER SURVIVORS 
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Since most patients with testicular cancer will be cured of their disease, this young 
population of survivors has been considered as a model to evaluate long-term toxic 
effects of diagnostic and therapeutic interventions. 
There is an emerging concern regarding the risk of secondary cancers due to exposure 
to diagnostic radiation in young patients with testicular cancer undergoing surveillance. 
A report of 2,569 patients observed for a median of 11 years showed no increased risk 
of secondary cancer in this group, although follow-up might not have been long enough 
to detect this risk.82 
The risk of secondary cancer from surgery, chemotherapy, and radiation therapy has 
been studied.83,84  Fung et al evaluated 12,691 patients treated with chemotherapy or 
surgery and reported a 40% increased risk for solid cancers for patients receiving 
chemotherapy.85 In testicular cancer survivors, cumulative doses of etoposide have 
been associated with an increased risk of developing secondary leukemia that typically 
exhibits a short latency period, a chromosomal translocation (11q23 and 21q22), and 
rearrangement of the mixed-lineage leukemia gene.83 The available data on testicular 
cancer suggest that the risk of secondary leukemia is dose-related, and that the risk of 
treatment with etoposide totaling more than 2 g is approximately 2% to 3%.69,86,87 
Testicular cancer survivors are also at risk for multiple late consequences of therapy 
including metabolic syndrome, cardiovascular disease, hypertension, infertility, 
neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, and psychosocial 
disorders.88-93 A multi-institutional study evaluating the genetic predisposition of long-
term cisplatin toxicities, identifying single nucleotide polymorphisms associated with 
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these toxicities, and collecting data regarding various cardiovascular risk factors in 
testicular cancer survivors is currently underway.  
CONCLUSIONS 
The modern history of testicular cancer is that of an oncological success story. The 
advances made in the diagnosis, prognostication, treatment, surgical expertise, and 
long-term survivorship care have resulted from collaborations among investigators 
across the globe. Collaborations are aimed at discovery of novel therapies for patients 
who are not cured by current therapeutic options and researching approaches for 
reducing the late effects of therapy. It is only with maintaining this collaborative spirit 
that researchers will hopefully achieve the unified goal of curing every patient with 
testicular cancer in the future.  
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Table 1. Treatment Options for Clinical Stage I Testicular Cancer 
Seminoma 
Option Outcomes Pros Cons References 
Active 
Surveillance 
20% relapse rate  
 
99% cancer 
specific survival 
Most men spared 
treatment 
 
Long-term 
outcomes are 
excellent even if 
patients relapse 
Many physician 
visits 
 
Life disruption if 
relapse 
Mortensen et al33 
Soper et al32 
Oldenburg et al39 
Radiotherapy 
4% relapse rate 
 
99% cancer 
specific survival 
Reduces risk for 
relapse  
 
Reduces risk for 
requiring 
chemotherapy 
 
Reduces frequency 
of abdominal 
imaging 
Short-term side 
effects 
 
Long-term risk of 
secondary cancer 
Soper et al32 
Oldenburg et al39 
Oliver et al31 
Carboplatin (one 
or two cycles) 
4% relapse rate 
 
99% cancer 
specific survival  
Reduces risk for 
relapse 
 
Reduces risk for 
requiring 
chemotherapy  
 
Short-term side 
effects of 
carboplatin 
 
Long-term risks of 
carboplatin are 
unknown  
Oldenburg et al39 
Oliver et al31 
Non-seminoma 
Active 
Surveillance 
30% relapse rate 
overall 
 
15% relapse rate if 
no risk factors 
 
50% relapse rate in 
high-risk group 
with risk facors 
 
99% cancer 
specific survival 
Most men spared 
treatment 
 
Long-term 
outcomes are 
excellent even if 
patients relapse 
Many physician 
visits 
 
Life disruption if 
relapse 
Kollmannsberger et 
al35 
Schmoll et al36 
Tandstad et al34 
 
Retroperitoneal 
Lymph Node 
Dissection 
20-30% relapse 
rate 
 
99% cancer 
specific survival 
Cures some 
patients with 
pathologic stage II 
disease 
 
Avoid the need for 
chemotherapy in 
some patients  
Surgical risk 
 
Most patients will 
have normal 
pathology in 
retroperitoneal 
lymph nodes 
 
Schmoll et al36 
Albers et al37 
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Disease does not 
recur in the 
retroperitoneum  
Chemotherapy 
might be required if 
patients relapse 
Bleomycin, 
Etoposide, 
Cisplatin (1 cycle) 
1-5% relapse rate 
 
99% cancer 
specific survival 
Reduces risk 
patients will require 
longer course of 
chemotherapy 
Early toxicity 
 
Overtreatment in 
substantial number 
of patients 
 
Long-term risk of 1 
or 2 cycles of 
chemotherapy is 
unknown  
Schmoll et al36 
Tandstad et al34 
Albers et al37 
Westermann et al38 
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Table 2. Treatment of Clinical Stage II Testicular Cancer 
Seminoma 
Option Indication Outcomes References 
Radiotherapy 
 
30-36 Gy to para-aortic 
and ipsilateral iliac lymph 
nodes 
Non-bulky disease 
(<3cm) 
5 year overall survival 
97% 
Domont et al42 
Schmoll et al41 
Chemotherapy 
 
BEPx3 or EPx4 
Bulky disease (>3cm) 5 year overall survival 98% 
Domont et al42 
Schmoll et al41 
Non-seminoma 
Retropertioneal Lymph 
Node Dissection 
Non-bulky disease 
(<3cm) 
5 year overall survival 
98% 
Donohue et al44 
Schmoll et al36 
Chemotherapy 
 
BEP x 3 or EP x4 
Bulky disease (>3cm) 5 year overall survival 98% Schmoll et al
36 
 
Abbreviations: BEP, bleomycin-etoposide-cisplatin; EP, etoposide-cisplatin 
 
 
 
 
 
 
 
 
 
31 
 
Table 3. First-line Treatment of Stage III Testicular Cancer 
Treatment Indication Outcomes References 
Good Risk Disease* 
 
Seminoma: any primary tumor site + no NPVM + any tumor marker levels (hCG, LDH) 
Non-seminoma: testis or retroperitoneal primary + no NPVM + good tumor marker levels (AFP < 
1,000 ng/mL, hCG < 5,000 mIu/mL, LDH < 1.5 x upper limit of normal) 
BEPx3 
 
 
 
 
 
EPx4 
For most patients 
 
 
Patients to avoid 
bleomycin (age>50, 
serum Cr>2) 
5 year PFS 90% 
 
5 year OS 97% 
Bosl et al3 
Williams et al6 
Einhorn et al5 
de Wit et al49 
Culine et al50 
Intermediate Risk*  
 
Seminoma: any primary tumor site + NPVM + any tumor marker level (hCG, LDH) 
Non-seminoma: testis or retroperitoneal primary + no NPVM + intermediate tumor marker levels 
(AFP 1,000-10,000 ng/mL, hCG 5,000-50,000 mIu/mL, LDH 1.5-10 x upper limit of normal) 
BEPx4 or VIPx4 
 
 
BEPx3 + EPx1 
For intermediate risk 
patients with high 
tumor bulk 
 
For low volume 
intermediate risk 
patients 
5 year PFS 84% 
 
5 year OS 93% 
de Wit et al52 
Nichols et al53 
Albany et al60 
Poor Risk Disease* 
 
Seminoma: none are poor risk 
Non-seminoma: Mediastinal primary OR NPVM OR poor tumor marker levels  
(AFP > 10,000 ng/mL, hCG > 50,000 mIu/mL, LDH > 10 x upper limit of normal) 
BEPx4 or VIPx4 For all patients 
5 year PFS 58% 
 
5 year OS 73% 
Nichols et al53 
Motzer et al55 
Droz et al56 
Daugaard et al57 
Fizazi et al58 
Adra et al59 
Abbreviations: NPVM, non-pulmonary visceral metastasis; BEP, bleomycin-etoposide-cisplatin; 
EP, etoposide-cisplatin; PFS, progression-free survival; OS, overall survival ; Cr, creatinine  
*Risk per IGCCCG (International Germ Cell Cancer Collaborative Group)  
 
